Aardvark Therapeutics (AARD) grants 44,964 options to director
Rhea-AI Filing Summary
Aardvark Therapeutics, Inc. (AARD) reported that director Susan E. Graf received a grant of 44,964 stock options to purchase Common Stock. The options have an exercise price of $6.54 per share, expire on August 14, 2036, and were awarded at no purchase price.
The options vest in full on the earlier of August 14, 2027 or immediately before the company’s next Annual Meeting of Stockholders following the grant date, subject to her continuous service through the vesting date. Following this grant, she holds 44,964 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Graf Susan E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 44,964 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 44,964 shares (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
Key Figures
Stock options granted: 44,964 options
Exercise price: $6.54 per share
Expiration date: August 14, 2036
+2 more
5 metrics
Stock options granted
44,964 options
Grant of Stock Option (right to buy) to Susan E. Graf
Exercise price
$6.54 per share
Exercise price of the granted stock options
Expiration date
August 14, 2036
Option expiration date for the granted stock options
Vesting date (latest)
August 14, 2027
Options vest earlier of this date or next Annual Meeting of Stockholders
Total options following transaction
44,964 options
Directly held by Susan E. Graf after the grant
Key Terms
Stock Option (right to buy), exercise price, expiration date, Annual Meeting of Stockholders
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "6.5400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-08-14""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting of Stockholders regulatory
"immediately prior to the Registrant's next Annual Meeting of Stockholders"
FAQ
What transaction did AARD director Susan E. Graf report?
Susan E. Graf reported receiving a grant of 44,964 stock options for Aardvark Therapeutics, Inc. common stock. The options were awarded at a $0.00 acquisition price with an exercise price of $6.54 per share and an expiration date of August 14, 2036.
What is the exercise price of the stock options granted to Susan E. Graf at AARD?
The stock options granted to Susan E. Graf have an exercise price of $6.54 per share. This is the price she must pay per share to purchase Aardvark Therapeutics, Inc. common stock upon exercising the options, subject to the options having vested.
When do Susan E. Graf’s AARD stock options vest?
The options vest in full on the earlier of August 14, 2027 or immediately prior to Aardvark Therapeutics, Inc.’s next Annual Meeting of Stockholders following the grant date, provided Susan E. Graf maintains continuous service through the applicable vesting date.
When do the AARD stock options granted to Susan E. Graf expire?
The stock options granted to Susan E. Graf expire on August 14, 2036. After this expiration date, any unexercised portion of the options will no longer be exercisable for Aardvark Therapeutics, Inc. common stock.
How many AARD options does Susan E. Graf hold after this grant?
After this grant, Susan E. Graf holds 44,964 stock options for Aardvark Therapeutics, Inc. common stock. These options are held directly according to the reported ownership information.
Does the Form 4 for AARD indicate any sales or purchases of common stock by Susan E. Graf?
No sales or market purchases of common stock are reported. The filing shows only a grant/award acquisition of 44,964 stock options with code A, which represents a compensation-related award rather than an open-market trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.
